NextCell Says ProTrans-Young Trial Results Delayed by Administrative Processing

Bitget2026/10/19 08:56

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NextCell Pharma's ProTrans-Young topline results remain pending following administrative delays unrelated to the study outcome.
Final data sign-off is complete; statisticians at Uppsala Clinical Research Center are handling the data.
The Uppsala University-sponsored trial includes 66 children and young adults with recently diagnosed type 1 diabetes.
Topline results will be published by press release once Principal Investigator Professor Per-Ola Carlsson receives them and shares them with NextCell.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCell Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202610190455BITN____UKPR__EN_20261019-BIT-6140-0) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NextCell Says ProTrans-Young Trial Results Delayed by Administrative Processing

You may also like

Crypto prices